-
Fulzerasib Tablets Approved with Conditions for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Fulzerasib Tablets (trade name:达伯特) of Innovent Biologics, Inc. is approved with condition for marketing through the priority review and approval procedure by China NMPA.
-
4 innovative products including implantable deep brain stimulation electrode lead kit approved for marketing
2024-05-28
Recently, the China NMPA approved the registration applications for 4 innovative products developed by Beijing PINS Medical Co., Ltd., including implantable deep brain stimulation electrode lead kit, dual channel rechargeable implantable deep brain stimulation pulse generator kit, dual channel implantable deep brain stimulation pulse generator kit and implantable deep brain stimulation extension lead kit.
-
Rezivertinib Mesylate Capsules approved for marketing by China NMPA
2024-05-20
Recently, the Class 1 innovative drug Rezivertinib Mesylate Capsules (trade name: 瑞必达) of Beta Pharma (Shanghai) Co., Ltd. is approved for marketing by China NMPA.
-
Crisugabalin Besilate Capsules approved for marketing by China NMPA
2024-05-20
Recently, the Class 1 innovative drug Crisugabalin Besilate Capsules (trade name: 思美宁) of Haisco Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for adult patients with diabetic peripheral neuropathic pain.
-
Repotrectinib capsules approved with conditions for marketing by China NMPA
2024-05-11
Recently, the Class 1 innovative drug Repotrectinib Capsules (trade name: 奥凯乐/AUGTYRO) of Bristol-Myers Squibb Company is approved for marketing with conditions through the priority review and approval procedure by China NMPA.
-
China Medical Device Standards Management Annual Report (2023)
2024-05-11
In 2023, China NMPA approved and issued 117 industry standard projects for medical devices, which were divided into formulation projects (57, 48.7%) and revision projects (60, 51.3%) according to the formulation and revision of standards.



